Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0K1SZ
|
||||
| Former ID |
DNC010191
|
||||
| Drug Name |
Norcisapride
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Gastroesophageal reflux disease [ICD9: 140-229, 530; ICD10:K21] | Discontinued in Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C14H20ClN3O3
|
||||
| Canonical SMILES |
COC1CNCCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl
|
||||
| InChI |
1S/C14H20ClN3O3/c1-20-12-6-10(16)9(15)5-8(12)14(19)18-11-3-4-17-7-13(11)21-2/h5-6,11,13,17H,3-4,7,16H2,1-2H3,(H,18,19)
|
||||
| InChIKey |
OMLDMGPCWMBPAN-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 4 receptor | Target Info | Inhibitor | [2] | |
| 5-hydroxytryptamine receptor 3A | Target Info | Inhibitor | [2] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapsehsa04726:Serotonergic synapse | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT4 type receptor mediated signaling pathwayP04375:5HT3 type receptor mediated signaling pathway | |||||
| PathWhiz Pathway | Excitatory Neural Signalling Through 5-HTR 4 and Serotonin | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (s) signalling eventsR-HSA-975298:Ligand-gated ion channel transport | |||||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP706:SIDS Susceptibility Pathways | |||||
| Iron uptake and transport | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007174) | ||||
| REF 2 | Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83. Epub 2009 Aug 8.mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.